Vancouver, British Columbia–(Newsfile Corp. – May 18, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“ Entheon” or the “Company“), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced it has entered into a drug-supply agreement (the “Agreement“) with Laboratorium Ofichem BV (“Ofichem” or “Ofichem Group”). Under the terms of the…


Previous articlePT244 – Mark Haberstroh – Mushrooms, Retreat Centers, and Safety
Next articleCybin Granted IRB Approval for Phase II Clinical Trials of its Sublingual Psilocybin Formulation for the Treatment of Major Depressive Disorder